Apricus Wealth cuts Merck stake by 23,115 shares
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Apricus Wealth LLC sold 23,115 Merck shares in the third quarter, retaining 18,213 shares worth about $2.65 million. Institutions hold 76.07% of the stock. Positive Phase 3 oncology results for Sac-TMT and KEYTRUDA are offset by KEYTRUDA patent expiration worries, China biotech partnership limits and insider selling. Analysts hold a Moderate Buy with a Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context